790 Memorial Drive
About KSQFounded by pre-eminent scientific leaders, KSQ Therapeutics, Inc. is a drug discovery company employing cutting-edge functional genomics technology to identify novel pathways and targets involved in oncology and immuno-oncology. We are developing this platform to uncover novel drug targets, mechanisms for drug efficacy and resistance to identify transformative single agent and combination therapies to benefit patients. We are looking for driven individuals who want to contribute to our fast growing company as a member of the founding scientific team. KSQ is backed by Flagship Ventures and Polaris Partners, two of the premier life science venture capital funds with over 30 years combined experience in launching and growing new biotechs.
Founder: Tim Wang
Please click here for KSQ Therapeutics job opportunities.
8 articles with KSQ
4/19/2019Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.
KSQ Therapeutics announced the appointment of Douglas Pagán as Chief Financial Officer.
KSQ Therapeutics announced the appointment of Beni B. Wolf, MD, PhD, as Chief Medical Officer.
According to consultant firm Frost & Sullivan, artificial intelligence (AI) systems will be the next big players in both global healthcare and individual gene editing. By 2021, the firm predicts that AI will be responsible for 6.7 billion dollars in revenue.
KSQ Therapeutics Secures $80 Million Financing and Advances Broad Pipeline of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program for PD-1 Resistant Solid Tumors
Company’s Pipeline Spans Three Oncology Drug Categories: Adoptive T-Cell Therapies, Immuno-Oncology Monotherapies and Targeted Therapies
Just this morning, KSQ Therapeutics disclosed that they’ve obtained an $80 million Series C financing that will be put towards the development of oncology drug candidates via CRISPRomics™, a drug discovery engine that creates insights specific to individual human genes on an industrial scale.
BlackThorn Therapeutics today announced the appointment of a key strategic executive to the company’s board of directors, George S. Golumbeski, Ph.D.